IVD Product Development: Navigating the Path from Concept to Commercial Launch

IVD product development is the regulated process of designing, validating, and commercializing diagnostic tests that analyze human specimens to guide clinical decisions. Unlike research-use assays, clinical IVDs must demonstrate analytical validity, clinical performance, and compliance with regulatory frameworks such as the FDA (U.S.) and IVDR (EU).

The lifecycle typically includes:

• Feasibility & Assay Design: Define intended use, select biomarkers, determine assay format (e.g., PCR, ELISA, NGS), and assess early risks.
• Analytical Development: Establish sensitivity, specificity, precision, reproducibility, stability, and interference controls.
• Verification & Validation (V&V): Confirm the device meets design inputs and performs reliably in clinical settings.
• Regulatory Submission & Manufacturing Scale-Up: Prepare 510(k), PMA, or IVDR documentation and transition to controlled production.

Success depends on integrating scientific rigor, ISO 14971 risk management, quality systems documentation, regulatory strategy, and scalable manufacturing planning from the earliest development stages.

In vitro diagnostics (IVDs) are at the center of every important decision in modern healthcare. When an IVD performs reliably, it improves nearly every aspect of healthcare — from the providers looking to make their processes more efficient and comprehensive to the patients receiving necessary treatment. When it fails — due to poor design controls, inadequate validation, or regulatory missteps — the consequences extend far beyond the laboratory.

Because of these consequences, development is not simply an exercise of assay optimization or device engineering. It is a tightly regulated, highly scrutinized process that demands scientific rigor, risk management discipline, and a deep understanding of evolving global regulatory frameworks. Juggling these priorities during every stage of development is something even the most established IVD developers may struggle with, especially if they’re also trying to release an IVD under a tight timeline. The key is to prioritize regulatory strategy from the start, which can often be difficult to do when you have constant stakeholder and consumer demands on the line.

This is when it becomes vital to enlist the help of a strategic, science-driven product development partner that can translate promising concepts into inspection-ready, commercially viable diagnostic products. At Arete, we work at the intersection of assay science, quality systems, and regulatory compliance to support that journey from concept to commercialization. To better understand the value of this approach, it helps to first explore what goes into IVD product development—and what’s at stake along the way.

What Is IVD Product Development?

At its core, IVD product development involves designing, validating, manufacturing, and commercializing diagnostic tests that analyze human specimens — such as blood, tissue, or urine — to generate clinically actionable information. Unlike research-use-only (RUO) assays or exploratory methods, the FDA in the U.S. and IVDR in the EU regulate clinical IVDs. To pass these regulations, developers must not only provide proof that the IVD simply works, but that it can be used safely, accurately, and consistently in clinical settings.

In many cases, such as molecular and companion diagnostics, clinical claims must align with therapeutic data and biomarker validation. These small scientific decisions can affect regulatory classification, submission requirements, and labeling claims, causing developers to shell out funds for costly redesigns.

To avoid these outcomes, IVD development should integrate three domains: scientific considerations, proactive regulatory strategy, and scalable manufacturing planning. In every stage of development, development teams should prioritize these goals, rather than focusing on one or the other. With this mindset, along with following a structured process, development teams can build IVDs with integrity, ensuring that each device is ready for inspections and manufacturing processes — all within the intended timeframe.

‍

‍

Key Stages of the IVD Product Development Lifecycle

As mentioned, one of the most vital ways to create effective IVDs is to follow a structured development process. This process should combine both developer and regulatory professionals to ensure each device can function as intended, meet regulatory standards, and be commercialized.

Feasibility and Assay Design

During the feasibility stage, product development teams determine whether a scientific concept can become a viable diagnostic product. They begin by selecting biomarkers and confirming that the biomarker is clinically relevant and measurable. They then make decisions on how the formatting of the assay will take place, either as an ELISA, PCR, lateral flow, or next-generation sequencing. This decision is based on performance requirements, the target user environment, instrument compatibility, and regulatory classification implications. Choosing the wrong format can complicate validation requirements or constrain future claims.

During this stage, early proof-of-concept studies take place. These studies don’t just confirm technical possibilities. They assess the risks that the ISO 14971 identifies. This includes failures like cross-reactivity, reagent instability, and variability across specimens. If these studies discover any of these risks, it’s vital to document and mitigate them before proceeding further in product development.

Throughout this stage, it’s essential to ensure IVD designs align with the intended clinical use. Even if the assay performs well analytically and doesn’t present any risks under ISO 14971, it could still struggle under regulatory scrutiny and market pressures if there isn’t a clear need for it in clinical settings.

Analytical Development and Optimization

If there is a clear demand for the IVD in clinical settings and it passes the feasibility stages, developing teams then define and refine its performance. This involves testing the IVD’s sensitivity, specificity, precision, reproducibility, linearity, and robustness. All of these factors establish the technical boundaries of the assay. Studies during this stage form the backbone of future submissions and are often executed alongside clinical, quality, and regulatory teams. Document everything, so your team can eventually trace back steps if any future missteps occur. In addition, documentation improves the likelihood of the IVD passing inspection.

Statistical rigor is also a priority during this stage. Reagent formulations may need adjustment, cutoffs need refinement, and control systems will need further strengthening in order to improve reproducibility and reduce variability. Design controls are also imperative. User needs should translate into design inputs, which should systematically receive testing through verification protocols.

In addition, many teams encounter the following challenges:

• Lot-to-lot variability: When assays produce inconsistent results, it can result from variations in raw materials or manufacturing conditions. If you don’t control these factors through robust specifications or quality checks, it can undermine reproducibility claims and trigger regulatory concerns during review or post-market surveillance.
• Matrix effects: Because biological samples contain complex components, such as proteins, lipids, hemoglobin, or anticoagulants, they may suppress or enhance signal detection. An assay that performs well during research phases may behave differently in clinical settings. Failing to replicate results in these settings may require teams to expand validation requirements.
• Interference from endogenous substances: Naturally occurring compounds, such as bilirubin, triglycerides, rheumatoid factor, or heterophilic antibodies, can produce false positives or false negatives. Interference testing is critical to rule out these outcomes across all patient populations, including those with common comorbidities.
• Stability limitations: Reagent, calibrator, and control stability directly affect shelf life, shipping conditions, and labeling claims. If IVDs are exposed to varying temperature fluctuations and light, it can shift their performance. Failing to regulate these factors can delay the development and review process.

If teams fail to address these challenges, they can cause significant issues during later stages. Therefore, even though mitigating and documenting these challenges may prolong the analytical development stage, it can streamline the overall process in the long run.

Verification and Validation (V&V)

During Verification and Validation (V&V), IVDs transition from formal development into regulatory readiness. On one side, verification confirms that the device meets predefined design inputs and demonstrates that the assay performs as engineered. On the other side, validation confirms the device performs as intended in the hands of target users through performance studies, illustrating that the IVD can work outside of research environments.

Both sides of this stage support labeling claims and regulatory submissions. If data at any point doesn’t indicate the device aligns with its intended use, regulators may reject it. Therefore, data integrity, statistical justification, and traceability are non-negotiable.

In addition, regulatory bodies like the FDA and the IVDR expect V&V to not only demonstrate that they perform well, but also that all development occurred in a compliant quality framework. To illustrate this, developers must provide risk management files, design history documentation, and study outcomes supported by clinical, quality, and regulatory expertise. All this documentation necessitates that teams work in a coordinated and organized manner, which can be difficult to do if you’re working with multiple design, development, and regulatory partners.

Manufacturing Scale-Up and Technology Transfer

As IVDs approach commercialization, industrial design and human factors considerations become critical to ensure usability, manufacturability, and consistent performance at scale. During this stage, manufacturers should ensure the IVD performs consistently across production lots and under routine manufacturing conditions, factoring in both light and temperature. Suppliers must demonstrate they are qualified to mitigate the risks associated with varying manufacturing decisions, which could affect the overall quality of the IVD.

To transfer to this stage, teams must have structured documentation, defined acceptance criteria, and process validation protocols. Informal handouts that lack this will result in batch failures, increased scrap rates, or further regulatory inspections.

If teams make any changes to IVDs to improve manufacturing or reproducibility, it could trigger additional validation from regulatory bodies, delaying commercialization even further. Therefore, teams must prioritize reproducibility from the very beginning.

‍

Regulatory Considerations in IVD Development

If the product development stages illustrate anything, it’s that regulatory considerations should not be an afterthought. They are an active determinant in every decision. They affect the timeline, the study designs, the documentation, and commercial decisions. Every IVD must pass the inspection by one or more of the following regulators, depending on the location where the IVD will be commercialized:

• FDA (U.S.)
• IVDR (EU)
• Health Canada (Canada)
• Medicines and Healthcare products Regulatory Agency (MHRA) (U.K).
• Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
• Therapeutic Goods Administration (TGA) (Australia)

Because most regulators require evidence that devices meet their classification requirements, development teams should account for them as early as conceptual stages. If your team makes a misjudgment about the risk class or predicate availability, it can alter the study’s scope, validation requirements, and submission timelines.

For example, if the IVD is a higher-risk classification, it will require more analytical validation, clinical performance data, quality system rigor, and post-market commitments. If development teams don’t design, analyze, and develop devices with this classification in mind, they may fail to generate data that meets submission standards, requiring a postponed submission.

Because of these stakes, all development and regulatory teams must collaborate in an organized and streamlined manner. On one side of the relationship, regulatory professionals will inform assay design, risk management, study protocols, and documentation organization. On the other side of the relationship, development teams must understand how their technical decisions could affect labelling claims, classification, and submission after the fact. If either team miscommunicates at any point or operates in isolation, they increase the likelihood of inspection findings, deficiency letters, or protracted review cycles. However, if the process is an equal give-and-take between both teams, then the IVD process becomes streamlined.

Common Challenges in IVD Product Development

Even with the proper oversight and analytical prowess, IVD product development carries inherent technical risk. Promising biomarkers can fail under real-world testing conditions. Assays that demonstrate signal characteristics in controlled environments may fail to reproduce similar results in clinical environments. Small shifts in reagent quality, calibration standards, or environmental conditions can all cause these results. Because of these issues, teams must identify and mitigate them early on in the development process. Otherwise, it could compromise the integrity of the studies and erode clinical confidence.

Simultaneously, regulatory bodies are constantly changing, affecting the approval process. For example, the recent adoption of the IVDR in the European Union has increased scrutiny around performance evaluation, clinical evidence, and post-market surveillance. Development teams that started conceptualizing IVDs before this adoption had to go back to the design stages in order to gain proper approval. As regulatory bodies continue to evolve and raise the bar for submission guidelines, all teams can do is put more effort into proactive planning. On a practical level, this includes more documentation and anticipating post-market data obligations.

Meanwhile, development and regulatory teams must factor in these hurdles under significant time pressures. Investors and commercial stakeholders often don’t realize all the stakes involved, and have expectations of how quickly development should take. However, giving in to this pressure without preserving analytical rigor can increase the risk of study failures or deficiencies that won’t pass through regulatory review.

Likewise, if a device requires repeat studies or amendments to pass through regulatory bodies, it could increase the overall cost of development. Extended labor, additional materials, and delayed revenue can all add up quickly. Therefore, proactive risk management and structured development adherence aren’t just a matter of quality of standards — they’re financial safeguards.

How Arete Biosciences Supports IVD Product Development

IVD product development isn’t an isolated process. It requires continuous collaboration and feedback from conceptualization and design to development and manufacturing. If you work with multiple partners to meet these goals to meet these goals, collaboration can falter. If your organization works alone, you may fail to meet investor expectations or timelines. In either scenario, Arete Biosciences can support your team for any development goal.

‍

We ground all of our work in scientific rigor and cross-functional expertise. Rather than treating compliance as an exercise in documentation, we use it as a framework, sourcing every stage with it in mind. This practice enables us to pass submission quality standards in a streamlined timeframe.

‍

We know that no product is the same, which is why we offer flexible engagement models. You can find support through our targeted advisory services to simply help with regulatory strategy or validation study design, or a more comprehensive partnership that involves our internal R&D and quality teams.

‍

No matter what you need, Arete Biosciences can help your team move from conceptualization to commercialization with ease, ensuring IVDs help the healthcare industry and the public for the better.

FAQs About IVD Product Development

What Is Considered an IVD Product?

An in vitro diagnostic (IVD) product is any test, assay, reagent, instrument, or system used to analyze human samples—such as blood, tissue, or saliva—to diagnose, monitor, or predict disease. This includes laboratory-developed tests (LDTs), companion diagnostics, and point-of-care assays. Because IVDs directly influence clinical decisions, they are subject to strict regulatory oversight.

How Long Does IVD Product Development Typically Take?

IVD product development timelines vary widely depending on assay complexity, regulatory pathway, and intended use. Early feasibility and assay development may take several months, while full validation and regulatory readiness can extend development to multiple years. Engaging experienced development partners early can significantly reduce delays caused by rework or regulatory misalignment.

What Regulatory Pathways Apply to IVD Products?

In the U.S., IVDs typically follow FDA pathways such as 510(k), De Novo, or PMA, depending on risk classification and predicate devices. In Europe, IVDs fall under the IVDR, which imposes more stringent clinical and performance evidence requirements. Global commercialization often requires aligning development activities with multiple regulatory frameworks simultaneously.

When Should Regulatory Strategy Be Considered During IVD Development?

Regulatory strategy should be integrated at the earliest stages of product development, ideally during feasibility and assay design. Early regulatory alignment helps ensure that development studies generate data suitable for submissions and reduces the risk of costly redesigns or additional validation later in the process.

Why Do Companies Outsource IVD Product Development?

Companies often outsource IVD product development to access specialized expertise, manage internal resource constraints, and reduce technical or regulatory risk. External partners can provide experienced teams, established quality systems, and scalable support that accelerates development while maintaining compliance.

‍